MARKET

CPHI

CPHI

CHINA PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5859
-0.0025
-0.42%
Closed 16:00 09/21 EDT
OPEN
0.5800
PREV CLOSE
0.5884
HIGH
0.6000
LOW
0.5750
VOLUME
125.74K
TURNOVER
--
52 WEEK HIGH
1.630
52 WEEK LOW
0.3501
MARKET CAP
25.53M
P/E (TTM)
-6.8366
1D
5D
1M
3M
1Y
5Y
BRIEF-China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
reuters.com · 08/13 20:33
China Pharma Holding Q2 EPS $(0.02), Sales $2.40M Down From $3.77M YoY
China Pharma Holding (AMEX:CPHI) reported quarterly losses of $(0.02) per share. The company reported $2.40 million in sales this quarter. This is a 36.36 percent decrease over sales of $3.77 million the same period
Benzinga · 08/13 20:32
China Pharma Swings to Q2 Net Loss As Revenue Drops Almost 36%
MT Newswires · 08/13 16:58
-- Earnings Flash (CPHI) CHINA PHARMA HOLDINGS Reports Q2 Revenue $2.4M
MT Newswires · 08/13 16:39
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results o...
PR Newswire · 08/05 13:00
China Pharma to Launch Highly Purified NMN+PQQ Product
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale tes...
PR Newswire · 06/09 12:00
BRIEF-China Pharma Holdings Posts Q1 Loss Per Share Of $0.02
reuters.com · 05/14 21:22
China Pharma reports Q1 results
China Pharma (CPHI): Q1 GAAP EPS of -$0.02.Revenue of $2.36M (+34.1% Y/Y)Press Release
Seekingalpha · 05/14 20:36
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPHI. Analyze the recent business situations of CHINA PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Zhilin Li
Director
Heung Tsui
Independent Director
Gene Bennett
Independent Director
Baowen Dong
Independent Director
Yingwen Zhang
No Data
About CPHI
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.

Webull offers kinds of China Pharma Holdings, Inc. stock information, including AMEX:CPHI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPHI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPHI stock methods without spending real money on the virtual paper trading platform.